Drug Profile


Alternative Names: INCB-024360; INCB-24360

Latest Information Update: 22 Jul 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer Bristol-Myers Squibb; Immunovaccine; Incyte Corporation; MedImmune; Merck AG
  • Class Amides; Antineoplastics; Imides; Oxadiazoles; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Phase I/II Colorectal cancer; Glioblastoma; Head and neck cancer
  • Preclinical Pancreatic cancer

Most Recent Events

  • 12 Jul 2017 University of Kansas plans a phase I trial in August 2017 for advanced Solid Tumor (Combination therapy, Late-stage disease) and Non-small Cell Lung Cancer (Combination therapy, Second line therapy or greater, Metastatic disease, recurrent, Late-stage disease) (NCT03217669)
  • 20 Jun 2017 Stanford University plans a phase II trial for Gastro-oesophageal junction and Gastric cancer (Combination therapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT03196232)
  • 07 Jun 2017 University of Pittsburgh, Incyte Corporation and Merck Sharp & Dohme plan a phase Ib/II trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) (NCT03182894)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top